AU3847997A – Inhibitors of the interaction between P53 and MDM2
– Google Patents
AU3847997A – Inhibitors of the interaction between P53 and MDM2
– Google Patents
Inhibitors of the interaction between P53 and MDM2
Info
Publication number
AU3847997A
AU3847997A
AU38479/97A
AU3847997A
AU3847997A
AU 3847997 A
AU3847997 A
AU 3847997A
AU 38479/97 A
AU38479/97 A
AU 38479/97A
AU 3847997 A
AU3847997 A
AU 3847997A
AU 3847997 A
AU3847997 A
AU 3847997A
Authority
AU
Australia
Prior art keywords
compounds
mdm2
interaction
human
inhibitors
Prior art date
1996-07-05
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU38479/97A
Inventor
Angelika Bottger
Volker Bottger
Patrick Chene
Pascal Furet
Carlos Garcia-Echeverria
Heinz-Kurt Hochkeppel
David Lane
Stephen Picksley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Campaign Technology Ltd
Original Assignee
Ciba Geigy AG
Novartis AG
Cancer Research Campaign Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
1996-07-05
Filing date
1997-07-04
Publication date
1998-02-02
1996-07-05
Priority claimed from GBGB9614197.3A
external-priority
patent/GB9614197D0/en
1997-04-07
Priority claimed from GBGB9707041.1A
external-priority
patent/GB9707041D0/en
1997-07-04
Application filed by Ciba Geigy AG, Novartis AG, Cancer Research Campaign Technology Ltd
filed
Critical
Ciba Geigy AG
1998-02-02
Publication of AU3847997A
publication
Critical
patent/AU3847997A/en
2001-01-15
Priority to AU14979/01A
priority
Critical
patent/AU777766B2/en
2002-01-31
Assigned to CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED
reassignment
CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED
Alteration of Name(s) of Applicant(s) under S113
Assignors: CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED, NOVARTIS AG
Status
Abandoned
legal-status
Critical
Current
Links
Espacenet
Global Dossier
Discuss
Classifications
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07K—PEPTIDES
C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
C07K7/04—Linear peptides containing only normal peptide links
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
A61P35/00—Antineoplastic agents
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K38/00—Medicinal preparations containing peptides
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07K—PEPTIDES
C07K2319/00—Fusion polypeptide
Abstract
The present invention relates to compounds capable of binding to the oncogene protein MDM2, processes for the preparation of such compounds, pharmaceutical preparations comprising such compounds, and uses of said compounds, e.g. in the therapeutic (including prophylactic) treatment of an animal or especially of the human body. The present further relates to methods of and compounds for inhibiting the growth of tumor cells which comprise the wild type p53 suppressor by interfering with the interaction between human p53 and human MDM2.
AU38479/97A
1996-07-05
1997-07-04
Inhibitors of the interaction between P53 and MDM2
Abandoned
AU3847997A
(en)
Priority Applications (1)
Application Number
Priority Date
Filing Date
Title
AU14979/01A
AU777766B2
(en)
1996-07-05
2001-01-15
Inhibitors of the interaction between p53 and MDM2
Applications Claiming Priority (5)
Application Number
Priority Date
Filing Date
Title
GB9614197
1996-07-05
GBGB9614197.3A
GB9614197D0
(en)
1996-07-05
1996-07-05
GB9707041
1997-04-07
GBGB9707041.1A
GB9707041D0
(en)
1997-04-07
1997-04-07
Inhibitors of the interaction between p53 and mdm2
PCT/EP1997/003549
WO1998001467A2
(en)
1996-07-05
1997-07-04
Inhibitors of the interaction between p53 and mdm2
Related Child Applications (1)
Application Number
Title
Priority Date
Filing Date
AU14979/01A
Division
AU777766B2
(en)
1996-07-05
2001-01-15
Inhibitors of the interaction between p53 and MDM2
Publications (1)
Publication Number
Publication Date
AU3847997A
true
AU3847997A
(en)
1998-02-02
Family
ID=26309649
Family Applications (1)
Application Number
Title
Priority Date
Filing Date
AU38479/97A
Abandoned
AU3847997A
(en)
1996-07-05
1997-07-04
Inhibitors of the interaction between P53 and MDM2
Country Status (8)
Country
Link
EP
(1)
EP0958305B1
(en)
JP
(1)
JP2001500365A
(en)
AT
(1)
ATE397621T1
(en)
AU
(1)
AU3847997A
(en)
CA
(1)
CA2259149A1
(en)
DE
(1)
DE69738754D1
(en)
NZ
(1)
NZ333609A
(en)
WO
(1)
WO1998001467A2
(en)
Families Citing this family (50)
* Cited by examiner, † Cited by third party
Publication number
Priority date
Publication date
Assignee
Title
US7083983B2
(en)
1996-07-05
2006-08-01
Cancer Research Campaign Technology Limited
Inhibitors of the interaction between P53 and MDM2
GB9708092D0
(en)
*
1997-04-22
1997-06-11
Univ Dundee
Materials and methods relating to inhibiting the interaction of p53 and mdm2
AU7238098A
(en)
*
1997-05-15
1998-12-08
Kyowa Hakko Kogyo Co. Ltd.
Peptides having cyclic structures and exerting p53 protein activty-restoring effect on p53 protein mutants
US6238921B1
(en)
*
1998-03-26
2001-05-29
Isis Pharmaceuticals, Inc.
Antisense oligonucleotide modulation of human mdm2 expression
EP0947494A1
(en)
*
1998-03-30
1999-10-06
F. Hoffmann-La Roche Ag
Derivatives of phenoxy acetic acid and phenoxymethyltetrazole having antitumor activity
ATE283915T1
(en)
*
1998-05-26
2004-12-15
Inst Of Molecul & Cell Biology
POLYPEPTIDES FROM CREB-BINDING PROTEIN AND RELATED PROTEIN P-300 FOR USE IN TRANSCRIPTIONAL REGULATION
GB9819860D0
(en)
*
1998-09-12
1998-11-04
Zeneca Ltd
Chemical compounds
US7192713B1
(en)
1999-05-18
2007-03-20
President And Fellows Of Harvard College
Stabilized compounds having secondary structure motifs
US20040038902A1
(en)
2000-04-05
2004-02-26
Pincus Matthew R.
Peptides selectively lethal to malignant and transformed mammalian cells
US7498336B2
(en)
2003-02-13
2009-03-03
The United States Of America As Represented By The Secretary, Department Of Health And Human Services
Deazaflavin compounds and methods of use thereof
WO2005044839A2
(en)
2003-11-05
2005-05-19
Dana-Farber Cancer Institute, Inc.
Stabilized alpha helical peptides and uses thereof
US8598127B2
(en)
*
2004-04-06
2013-12-03
Korea Research Institute Of Bioscience & Biotechnology
Peptides for inhibiting MDM2 function
AU2004319946A1
(en)
*
2004-04-22
2005-12-01
3-Dimensional Pharmaceuticals, Inc.
HDM2-inhibitor complexes and uses thereof
ES2558928T3
(en)
2007-01-31
2016-02-09
Dana-Farber Cancer Institute, Inc.
Stabilized p53 peptides and uses thereof
JP5631201B2
(en)
2007-03-28
2014-11-26
プレジデント アンド フェローズ オブ ハーバード カレッジ
Stitched polypeptide
WO2010083347A2
(en)
2009-01-14
2010-07-22
Aileron Therapeutics, Inc.
Peptidomimetic macrocycles
US20120135917A1
(en)
*
2009-06-16
2012-05-31
Eisaku Yoshihara
Anti-Gram Negative Bacteria Agent
WO2011005219A1
(en)
*
2009-07-07
2011-01-13
Agency For Science, Technology And Research
Novel mdm2 binding peptides and uses thereof
CA2771936A1
(en)
2009-08-26
2011-03-03
Novartis Ag
Tetra-substituted heteroaryl compounds and their use as mdm2 and/or mdm4 modulators
JP2013505300A
(en)
2009-09-22
2013-02-14
エルロン・セラピューティクス・インコーポレイテッド
Peptidomimetic macrocycle
CU24130B1
(en)
2009-12-22
2015-09-29
Novartis Ag
ISOQUINOLINONES AND REPLACED QUINAZOLINONES
US8440693B2
(en)
2009-12-22
2013-05-14
Novartis Ag
Substituted isoquinolinones and quinazolinones
PL2603600T3
(en)
2010-08-13
2019-06-28
Aileron Therapeutics, Inc.
Peptidomimetic macrocycles
US8859535B2
(en)
2011-06-20
2014-10-14
Novartis Ag
Hydroxy substituted isoquinolinone derivatives
US8859586B2
(en)
2011-06-20
2014-10-14
Novartis Ag
Cyclohexyl isoquinolinone compounds
TWI643868B
(en)
2011-10-18
2018-12-11
艾利倫治療公司
Peptidomimetic macrocycles
KR20150000468A
(en)
*
2011-11-09
2015-01-02
메르츠 파마 게엠베하 운트 코. 카가아
Neurotoxins exhibiting shortened biological activity
US9408885B2
(en)
*
2011-12-01
2016-08-09
Vib Vzw
Combinations of therapeutic agents for treating melanoma
SG11201404648PA
(en)
2012-02-15
2014-09-26
Aileron Therapeutics Inc
Peptidomimetic macrocycles
CA2864120A1
(en)
2012-02-15
2013-08-22
Aileron Therapeutics, Inc.
Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
US9365576B2
(en)
2012-05-24
2016-06-14
Novartis Ag
Pyrrolopyrrolidinone compounds
SG11201503052RA
(en)
2012-11-01
2015-05-28
Aileron Therapeutics Inc
Disubstituted amino acids and methods of preparation and use thereof
WO2014115077A1
(en)
2013-01-22
2014-07-31
Novartis Ag
Substituted purinone compounds
EP2948453B1
(en)
2013-01-22
2017-08-02
Novartis AG
Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
MX2015016344A
(en)
2013-05-27
2016-03-01
Novartis Ag
Imidazopyrrolidinone derivatives and their use in the treatment of disease.
PT3004108T
(en)
2013-05-28
2018-01-24
Novartis Ag
Pyrazolo-pyrrolidin-4-one derivatives as bet inhibitors and their use in the treatment of disease
KR20160012197A
(en)
2013-05-28
2016-02-02
노파르티스 아게
Pyrazolo-pyrrolidin-4-one derivatives and their use in the treatment of disease
EA029269B1
(en)
2013-11-21
2018-02-28
Новартис Аг
Pyrrolopyrrolone derivatives and their use for treating diseases
SG11201702175YA
(en)
2014-09-24
2017-04-27
Aileron Therapeutics Inc
Peptidomimetic macrocycles and formulations thereof
CA2961258A1
(en)
2014-09-24
2016-03-31
Aileron Therapeutics, Inc.
Peptidomimetic macrocycles and uses thereof
CA2979847A1
(en)
2015-03-20
2016-09-29
Aileron Therapeutics, Inc.
Peptidomimetic macrocycles and uses thereof
US10059741B2
(en)
2015-07-01
2018-08-28
Aileron Therapeutics, Inc.
Peptidomimetic macrocycles
CN108368161A
(en)
2015-09-10
2018-08-03
艾瑞朗医疗公司
Peptidomimetic macrocyclic compound as MCL-1 conditioning agents
WO2017201449A1
(en)
2016-05-20
2017-11-23
Genentech, Inc.
Protac antibody conjugates and methods of use
CN112119085A
(en)
2017-12-15
2020-12-22
丹娜-法伯癌症研究院有限公司
Stable peptide-mediated targeted protein degradation
US11091522B2
(en)
2018-07-23
2021-08-17
Aileron Therapeutics, Inc.
Peptidomimetic macrocycles and uses thereof
CN109206474A
(en)
*
2018-11-27
2019-01-15
青岛海洋生物医药研究院
A kind of linear peptide symthesis method
US20220153868A1
(en)
*
2019-02-20
2022-05-19
Oncolyze, Inc
Hdm2 antibody for use in treating cancer
CN112266407B
(en)
*
2020-09-28
2023-05-12
宁夏医科大学总医院
Heptapeptide specifically combined with p53 protein, coding gene, preparation method and application
WO2023056069A1
(en)
2021-09-30
2023-04-06
Angiex, Inc.
Degrader-antibody conjugates and methods of using same
1997
1997-07-04
JP
JP10504775A
patent/JP2001500365A/en
not_active
Withdrawn
1997-07-04
CA
CA002259149A
patent/CA2259149A1/en
not_active
Abandoned
1997-07-04
DE
DE69738754T
patent/DE69738754D1/en
not_active
Expired – Fee Related
1997-07-04
EP
EP97935511A
patent/EP0958305B1/en
not_active
Expired – Lifetime
1997-07-04
AU
AU38479/97A
patent/AU3847997A/en
not_active
Abandoned
1997-07-04
WO
PCT/EP1997/003549
patent/WO1998001467A2/en
active
IP Right Grant
1997-07-04
NZ
NZ333609A
patent/NZ333609A/en
unknown
1997-07-04
AT
AT97935511T
patent/ATE397621T1/en
not_active
IP Right Cessation
Also Published As
Publication number
Publication date
EP0958305B1
(en)
2008-06-04
ATE397621T1
(en)
2008-06-15
JP2001500365A
(en)
2001-01-16
CA2259149A1
(en)
1998-01-15
EP0958305A2
(en)
1999-11-24
NZ333609A
(en)
2000-08-25
DE69738754D1
(en)
2008-07-17
WO1998001467A2
(en)
1998-01-15
Similar Documents
Publication
Publication Date
Title
AU3847997A
(en)
1998-02-02
Inhibitors of the interaction between P53 and MDM2
GR3036188T3
(en)
2001-10-31
Substituted tetra- and pentapeptide inhibitors of protein:farnesyl transferase
AU7079396A
(en)
1997-04-17
Anti-galalpha(1,3)gal antibody binding peptides
AU4612093A
(en)
1994-03-10
Soluble ligands for CD40
GEP20043363B
(en)
2004-05-10
Indazole Compounds, Pharmaceutical Compositions, and Methods for Inhibiting Cell Proliferation
AU2987695A
(en)
1996-02-16
Interruption of binding of mdm2 and p53 protein and therapeutic application thereof
EP1090924B8
(en)
2007-11-21
Tumor antigen peptides originating in cyclophilin b
MX9707431A
(en)
1997-12-31
Protein kinase c inhibitors.
UA43348C2
(en)
2001-12-17
Aqueous pharmaceutical composition, which includes the factor of the nerve growth factor (variants) and liophilic pharmaceutical composition
WO2003089456A3
(en)
2004-02-12
Peptide inhibitors of protein kinase c
HRP950337B1
(en)
2001-12-31
Histidine and homohistidine derivatives as inhibitors of protein farnesyltransferase
AU6933496A
(en)
1997-03-27
Antagonists of the oncogenic activity of the MDM2 protein and their use in the treatment of cancers
IL187254A
(en)
2010-12-30
ANTISENSE NUCLEOTIDES, COMPOSITIONS COMPRISING THEREOF AND THEIR USE IN MODULATING ACTIVATION OF NF-kB
EP0678031A4
(en)
1996-07-17
Tissue-derived tumor growth inhibitors, methods of preparation and uses thereof.
CA2234263A1
(en)
1998-02-05
Pharmaceutical composition for treating papillomavirus tumours and infection
AU6745287A
(en)
1987-07-16
Dna sequences coding for proteins having the biological activity of husi-type i inhibitors, biotechnological methods for the preparation of said proteins and pharmaceutical compositions containing said proteins
WO2001018046A3
(en)
2001-09-13
Ovarian tumor sequences and methods of use therefor
IE871967L
(en)
1989-01-22
Binding-factor-related polypeptides
WO2002092013A3
(en)
2004-11-04
Methods for treating liver disease and liver damage with growth hormone and foxm1b
AU3390995A
(en)
1996-03-29
Novel implant and novel vector for the treatment of acquired diseases
WO2001029226A3
(en)
2002-02-07
Apoptosis inducing proteinaceous substance
EP0821969A3
(en)
2000-12-13
Medicinal Composition comprising TCF-II
WO2001040465A3
(en)
2002-03-21
Compositions and methods for the treatment of immune related diseases
PL336897A1
(en)
2000-07-17
Novel salts of bpc peptides, pharmaceutic compositions conatining them and method of obtaining such salts
AU2001220255A1
(en)
2001-11-07
Human cervical cancer suppressor protein, polynucleotide encoding the protein, cell transformed with the polynucleotide and method for suppressing proliferationof cancer cell using the expression vector
Legal Events
Date
Code
Title
Description
2001-02-22
MK5
Application lapsed section 142(2)(e) – patent request and compl. specification not accepted
2002-01-31
PC1
Assignment before grant (sect. 113)
Owner name:
CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED
Free format text:
THE FORMER OWNER WAS: NOVARTIS AG, CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED
